Cart
sales@molnova.com
BIA
CAS No. 134271-74-2
BIA( —— )
Catalog No. M23500 CAS No. 134271-74-2
BIA is an inhibitor of the interaction between TMBIM6 and mTORC2, which ultimately blocks AKT activation and cancer progression.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 53 | In Stock |
|
| 10MG | 87 | In Stock |
|
| 25MG | 177 | In Stock |
|
| 50MG | 286 | In Stock |
|
| 100MG | 430 | In Stock |
|
| 500MG | 888 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBIA
-
NoteResearch use only, not for human use.
-
Brief DescriptionBIA is an inhibitor of the interaction between TMBIM6 and mTORC2, which ultimately blocks AKT activation and cancer progression.
-
DescriptionBIA is an inhibitor of the interaction between TMBIM6 and mTORC2, which ultimately blocks AKT activation and cancer progression.
-
In VitroCDC25B-IN-2 (compound 27; 20 μg/mL) has cdc25B enzyme inhibitory activities 16.11% in vitro.
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptorTMBIM6
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number134271-74-2
-
Formula Weight268.27
-
Molecular FormulaC15H12N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (931.90 mM)
-
SMILESO=C(C1=CC=CC=C1N)/C=C/C2=CC=CC([N+]([O-])=O)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kim H K , Bhattarai K R , Junjappa R P , et al. TMBIM6/BI-1 contributes to cancer progression through assembly with mTORC2 and AKT activation[J]. Nature Communications, 2020, 11(1).
molnova catalog
related products
-
Seco Rapamycin
Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.
-
SR9011
SR9011 is a REV-ERB agonist (IC50: 790 nM, REV-ERBα; IC50: 560 nM, REV-ERBβ).
-
AZD-8055
A potent, selective, ATP-competitive and orally bioavailable mTOR inhibitor with IC50 of 0.8 nM.
